Category: End of life care

Discovering the medicines of tomorrow: Four lessons from failed Alzheimer’s research

By guest blogger Chanice Henry, Editor, Pharma IQ

Even though drug development for Alzheimer’s Disease has a steep failure rate, the lessons learned from failed trials are of great benefit to future research.

Alzheimer’s is the most common form of dementia – the irreversible loss of memory and other cognitive functions which eventually makes daily tasks unmanageable.

As the life expectancy of the world’s population grows, the Alzheimer’s is becoming more common. Estimates suggest that  the number of affected US patients will climb from 5.3 million to almost 14 million by 2050.

In the fight against this disease many have dedicated their careers to revolutionise how the neurodegenerative disease is diagnosed and handled.

The importance of the Access to Palliative Care Bill 2015

By Mark Steedman from the Institute of Global Health Innovation

The Access to Palliative Care Bill is to be given its second reading tomorrow (23rd October). While palliative care is widely viewed to be excellent in the UK, there are gaps in access to it, and this Bill hopes to eliminate these gaps.

The Bill’s stated aim is to “make provision for equitable access to palliative care services; for advancing education, training and research in palliative care; and for connected purposes”.

I’ve now worked in palliative care for two and a half years, and despite the knowledge I’ve gained and the progress I’ve seen, I’m still amazed at the reception I get when I speak at conferences.